Clinical Trial

A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Flumatinib is an orally available TKI with high selectivity and potency against BCR-ABL1 kinase. It's a multi-center, open-label, real world study to explore the efficacy and safety of Flumatinib versus Imatinib as the first line therapy in patients with chronic myleiod leukemia(CML) in chronic phase(CP).
Trial Details
NCT Number NCT05367765
Lead Sponsor Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions CML, Chronic Phase
Enrollment 2,400 participants
Start Date 2022-04-30
Primary Completion 2027-04-30 (estimated)
Study Completion 2028-04-30 (estimated)
Updated on ClinicalTrials.gov 2022-05-10